Oral polyphenol-armored nanomedicine for targeted modulation of gut microbiota-brain interactions in colitis.
Huan HeQiaozhen QinFang XuYitong ChenShuquan RaoChao WangXiao-Xia JiangXiong LuChaoming XiePublished in: Science advances (2023)
Developing oral nanomedicines that suppress intestinal inflammation while modulating gut microbiota and brain interactions is essential for effectively treating inflammatory bowel disease. Here, we report an oral polyphenol-armored nanomedicine based on tumor necrosis factor-α (TNF-α)-small interfering RNA and gallic acid-mediated graphene quantum dot (GAGQD)-encapsulated bovine serum albumin nanoparticle, with a chitosan and tannin acid (CHI/TA) multilayer. Referred to "armor," the CHI/TA multilayer resists the harsh environment of the gastrointestinal tract and adheres to inflamed colon sites in a targeted manner. TA provides antioxidative stress and prebiotic activities that modulate the diverse gut microbiota. Moreover, GAGQD protected TNF-α-siRNA delivery. Unexpectedly, the armored nanomedicine suppressed hyperactive immune responses and modulated bacterial gut microbiota homeostasis in a mouse model of acute colitis. Notably, the armored nanomedicine alleviated anxiety- and depression-like behaviors and cognitive impairment in mice with colitis. This armor strategy sheds light on the effect of oral nanomedicines on bacterial gut microbiome-brain interactions.
Keyphrases
- cancer therapy
- drug delivery
- resting state
- rheumatoid arthritis
- white matter
- mouse model
- immune response
- cognitive impairment
- functional connectivity
- oxidative stress
- ulcerative colitis
- cerebral ischemia
- type diabetes
- liver failure
- toll like receptor
- signaling pathway
- respiratory failure
- subarachnoid hemorrhage
- inflammatory response
- drug induced
- room temperature
- stress induced
- ionic liquid